Veraxa Biotech AG is a clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer therapies. The company works on antibody-drug conjugates and bispecific antibody formats, using proprietary screening and bioconjugation technologies to create targeted oncology candidates. Its current pipeline centers on drug programs in acute myeloid leukemia and other cancer indications, reflecting a focus on precise, mechanism-driven treatment approaches. Veraxa Biotech AG also develops platform capabilities intended to support the identification, engineering, and optimization of therapeutic antibodies for internal programs and collaborative partnerships. Based in Zurich, Switzerland, with research and development operations in Heidelberg, Germany, the company operates within the oncology biotechnology market and contributes to the broader advancement of next-generation biologic medicines.